VS, and GVG
guidelines, clopidogrel is considered as the antiplatelet
agent of choice in those with PAD. This recommendation
is in particular based on The Clopidogrel versus Aspirin in
Patients at Risk for Ischaemic Events (CAPRIE) trial, in
which clopidogrel was more effective in reducing cardiovascular risk without an increased risk of bleeding.133
It should be noted that only a subset of participants in
